Zydus partners with CVS Caremark to add Zituvio™, Zituvimet™ and Zituvimet™ XR to its template formulary

Zydus Lifesciences Ltd. has entered into an agreement with CVS Caremark®, a CVS Health® company to add Zituvio™, Zituvimet™ and Zituvimet™ XR (Sitagliptin | Sitagliptin and Metformin Hydrochloride) tablets to its template formulary. The agreement will come into effect from January 1, 2025. The Zituvio range of products contain active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCI), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This partnership is a strong validation of Zydus’ strategic investments in 505(b)(2) portfolio and will set the way for further strengthening the portfolio of differentiated products in the US market.